Skip to content
Download PDF

Exercise Intolerance

Chapter 46 | Part 2: Cardiovascular Diseases · Part 2 – Cardinal Manifestations & Presentation · Chapter 46

Key Clinical Points

  1. Exercise intolerance is defined as the inability to perform physical activity at a level expected for a person of a given age, sex, body mass, and muscle mass.
  2. It is a common symptom in diverse conditions including ischemic heart disease, valvular heart disease, heart failure, COPD, ILD, cystic fibrosis, pulmonary hypertension, stroke, neuromuscular disorders, and postinfection syndromes.
  3. Patients with these conditions who manifest exercise intolerance often have an increased rate of disease progression and higher mortality.
  4. The pathophysiology is defined by the rate of oxygen consumption at peak exercise (VO2max).
  5. Cardiopulmonary exercise testing (CPET) is the primary diagnostic tool to identify specific sites of impairment in the oxygen delivery/utilization pathway.
  6. In HFpEF, impaired skeletal muscle diffusion of O2 is the most frequent cause of exercise intolerance.
  7. Long COVID-associated fatigue and exercise intolerance may involve oxidative stress, altered energy metabolism, gut dysbiosis, and cardiac deconditioning.
  8. Precision medicine in HFpEF involves identifying the specific set of causes (e.g., pulmonary vs. cardiac) driving a patient's symptoms.
  9. Focused exercise prescriptions tailored to individual pathophysiology can improve outcomes in many patients with Long COVID.

DEFINITION & OVERVIEW

• Definition: The inability to perform physical activity at a level expected for a person of a given age, sex, body mass, and muscle mass. • Clinical Significance: ◦ Common symptom in many chronic diseases: ◦ Ischemic heart disease ◦ Valvular heart disease ◦ Heart failure ◦ Chronic obstructive pulmonary disease (COPD) ◦ Interstitial lung disease (ILD) ◦ Cystic fibrosis ◦ Pulmonary hypertension ◦ Stroke ◦ Neuromuscular disorders ◦ Postinfection syndromes ◦ Prognostic Value: While not all patients with these conditions manifest exercise intolerance, those who do often have an increased rate of disease progression and higher mortality. ◦ Impact: Significantly reduces quality of life.

PATHOPHYSIOLOGY

• Measurement: Exercise capacity is physiologically defined by the rate of oxygen consumption (VO2) at peak exercise (VO2max). • Mechanism: Any factor impairing O2 delivery or utilization reduces VO2max and causes exercise intolerance. • Oxygen Delivery and Utilization Pathway (Figure 46-1): The following sequence represents the physiological pathway; impairment at any step leads to decreased exercise capacity: Inspired O2 → Alveolar ventilation → Lung diffusing capacity → Hemoglobin transport → Cardiac output → Microvascular perfusion → Muscle diffusion → Mitochondrial respiration. • Table 46-1: Oxygen Delivery and Utilization Pathway ◦ Step 1: Reduced inspired O2 concentration → Decreased exercise capacity ◦ Step 2: Reduced alveolar ventilation → Decreased exercise capacity ◦ Step 3: Impaired lung diffusion (alveolus to capillary) → Decreased exercise capacity ◦ Step 4: Reduced hemoglobin concentration or transport → Decreased exercise capacity ◦ Step 5: Decreased cardiac output → Decreased exercise capacity ◦ Step 6: Impaired diffusion of O2 into (skeletal) muscle → Decreased exercise capacity ◦ Step 7: Impaired mitochondrial respiration → Decreased exercise capacity

SIGNS AND SYMPTOMS

• General Presentation: ◦ Severity varies by etiology. ◦ Examples: ◦ Heart failure (post-MI): May be unable to walk up a flight of stairs yet feel comfortable at rest. ◦ Pulmonary arterial hypertension: Short of breath with minimal exertion. ◦ Symptoms of severe intolerance: Unusual breathlessness or dyspnea at rest accompanied by tachypnea, (sinus) tachycardia, muscle fatigue, weakness, or frank myalgias. • Heart Failure with Preserved Ejection Fraction (HFpEF): ◦ Multi-factorial etiology (Table 46-2). ◦ Key Determinants: ◦ Skeletal Muscle: Impaired skeletal muscle diffusion of O2 (Most frequent cause) ◦ Cardiac: Reduced cardiac output (Common) ◦ Ventilation: Decreased alveolar ventilation (Common) ◦ Lung: Reduced lung diffusing capacity (Common) ◦ Hematologic: Anemia (Common) ◦ Additional Factors: ◦ Increased large artery stiffness ◦ Chronotropic incompetence ◦ Microvascular dysfunction (endothelium-dependent and endothelium-independent) ◦ Inflammation, adipokine signaling, and insulin resistance in obese diabetics. ◦ Internal Work: A body mass index–related measure of the cost of initiating movement; higher in HFpEF patients → associated with rapid increases in cardiac filling pressures (and pulmonary capillary wedge pressure) early in exercise. • Long COVID Syndrome: ◦ Presentation: Similar to myalgic encephalomyelitis (but less typically includes postexertional malaise). ◦ Timeline: Exertional dyspnea, fatigue, and anxiety for up to 3 months after acute infection; fatigue remains the most common symptom thereafter. ◦ Autonomic Dysfunction: Orthostatic intolerance and positional tachycardia are common. ◦ Mechanisms: Multiple causes, oxidative stress, altered energy metabolism, gut microbiome dysbiosis, and cardiac deconditioning.

INVESTIGATIONS

  1. Diagnostic Strategy: • Determine if a single cause is evident (e.g., decreased cardiac output in HFrEF) or if multiple causes are present.
  2. Cardiopulmonary Exercise Testing (CPET): • Primary tool when the specific site of impairment is unclear or multiple factors exist. • Standard CPET Components: ◦ Measurement of breath-by-breath O2 consumption and CO2 production. ◦ Continuous electrocardiogram (ECG) recording during stationary cycle ergometry. • Advanced CPET Components: ◦ Intracardiac (right-heart) pressures measured during exercise. ◦ Arterial blood gases and lactate measured before, during, and after exercise. • Purpose: Provides additional diagnostic information to identify the underlying physiologic etiology of exercise limitation.

MANAGEMENT & TREATMENT

  1. Precision Medicine Approach: • Basis: Ascertain the specific set of causes in any individual patient (e.g., identifying which components of the oxygen delivery pathway are impaired). • Application: Used for HFpEF and other diseases with multi-factorial exercise intolerance.
  2. Targeted Intervention: • Strategy: Focused exercise prescriptions guided by patient-specific pathophysiology.
  3. Long COVID Management: • Goal: Address specific underlying mechanisms to relieve symptoms. • Targets: ◦ Oxidative stress management ◦ Altered energy metabolism correction ◦ Gut microbiome dysbiosis treatment ◦ Cardiac deconditioning rehabilitation

DIAGNOSTIC CLUES

• HFpEF Specific Clues: ◦ Inability to walk up a flight of stairs while comfortable at rest. ◦ Rapid increases in cardiac filling pressures (and pulmonary capillary wedge pressure) early in exercise related to high 'internal work'. ◦ Presence of multi-factorial drivers: impaired muscle diffusion, reduced cardiac output, and impaired ventilation. • Long COVID Specific Clues: ◦ Exertional dyspnea, fatigue, and anxiety for up to 3 months post-infection. ◦ Persistent fatigue as the primary symptom after 3 months. ◦ Orthostatic intolerance and positional tachycardia (indicators of autonomic dysfunction). • General Red Flags: ◦ Unusual breathlessness or dyspnea at rest accompanied by tachypnea, (sinus) tachycardia, muscle fatigue, weakness, or frank myalgias.